FDA Grants Breakthrough Therapy Designation for Tucatinib in HER2-Positive Breast Cancer
Seattle Genetics announced the development after data was presented at the 2019 San Antonio Breast Cancer Symposium.
Related Articles
Ramucirumab Maintenance Combo Shows Benefit in HER2– Gastric/GEJ Cancer
Phase 3 data support ramucirumab/paclitaxel switch maintenance as a post-induction therapy for patients who are not eligible for immunotherapy.
Selinexor Maintenance Improves PFS in TP53 Wild-Type Endometrial Cancer
The median PFS in patients with pMMR TP53 wild-type endometrial cancer was 39.5 months with selinexor and 4.9 months with placebo.
Orca-T Displays cGVHD-Free Survival Benefit in Hematologic Malignancies
Overall survival outcomes were enhanced with Orca-T vs allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer
Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.
Renal Cell Carcinoma Treatment Algorithm
Rohit Gosain, MD; Rahul Gosain, MD; and Katy Beckermann, MD, PhD, discuss advances in renal cell carcinoma treatment, including adjuvant pembrolizumab following KEYNOTE-564 data, management…
Updated Nivolumab Data Solidify Use in Advanced Gastric/GEJ/Esophageal Cancers
Results from the CheckMate649 trial support the use of nivolumab plus chemotherapy in the treatment of advanced gastric cancers.
EC Approved Liso-cel in Pretreated Relapsed/Refractory Follicular Lymphoma
Liso-cel has been approved by the European Commission for the treatment of adult patients with follicular lymphoma who received 2 or more prior lines of…
Cancer Network
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
Afuresertib/Paclitaxel Shows No Survival Difference vs Paclitaxel in PROC
Although there was no statistical significance in survival data, afuresertib/paclitaxel improved PFS vs paclitaxel in patients with the pAKT biomarker.
Cadonilimab Combo Shows Encouraging Activity in Advanced Endometrial Cancer
Cadonilimab plus lenvatinib appeared to have a manageable safety profile in a phase 2 trial.